Divi's Laboratories Ltd.
Snapshot View

4843.80 -46.80 ▼-1.0%

29 July 2021, 04:02:36 P.M.
Volume: 658,995

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.divislaboratories.com
Financial Indicators
Market Cap 128,656.69 Cr.
Earnings per share (EPS) 74.75 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 64.84 Trailing Twelve Months Ending 2021-03
Industry PE 34.39 Trailing Twelve Months Ending 2021-03
Book Value / Share 350.12 Trailing Twelve Months Ending 2021-03
Price to Book Value 13.84 Calculated using Price: 4,846.40
Dividend Yield 0.41 Period Ending 2020-03
No. of Shares Subscribed 26.55 Cr. 265,468,580 Shares
FaceValue 2
Company Profile

Divi’s Laboratories Limited is a Company limited by shares, incorporated and domiciled in India. The Company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. The Company is a public limited company and the Company’s equity shares are listed in BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) in India.

Business area of the company

The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.

Business Segments

  • Generic APIs
  • Custom Synthesis
  • Nutraceuticals

Products

  • Capecitabine 
  • Carbidopa
  • Diltiazem HCl 
  • Dextromethorphan Base 
  • Dextromethorphan HBr 
  • Fosphenytoin Sodium 
  • Gabapentin 
  • Iopamidol
  • Irbesartan 
  • Levetiracetam
  • Levodopa
  • Mesalamine 
  • Nabumetone 
  • Naproxen
  • Naproxen Sodium 
  • Niacin
  • Olmesartan Medoxomil 
  • Phenylephrine HCl 
  • Pregabalin
  • Proguanil HCl 
  • Quetiapine Fumarate 
  • Tamsulosin HCl 
  • Telmisartan 
  • Triprolidine HCl 
  • Valacyclovir HCl 
  • Valsartan 
  • Venlafaxine HCl 
  • Vigabatrin 

Awards

2001:

  • Occupational Health and Safety Management System (OHSAS-18001) 

2002:

  • May Day Award for Best Management 

2003:

  • Shreshtha Suraksha Puraskar 
  • Appreciation certificate for Meritorious performance in implementing the programmes of ‘Safe Guarding the Environment and Pollution Control’
  • Viswakarma Rashtriya Puraskar  

2004:

  • Good Practice in Cleaner Production and Pollution Control 

2005:

  • National Award for Excellence Water Management 2005 
  • Appreciation certificate for Meritorious performance in implementing the programmes of ‘Safe Guarding the Environment and Pollution Control & Plantation work’. 
  • May Day Award for Best Management 

2006:

  • National Award for Excellence Water Management and Certificate for Water efficient unit.
  • National Award for Excellence Water Management and Certificate for Water efficient unit - Beyond the fence. 
  • Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’. 

2007:

  • Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’. 

2008:

  • Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’ on the Occasion of the World Environment 
  • Finalist Certificate 

2009:

  • Certified and Awarded for ‘Best Green Belt Development’
  • Occupational Health and Safety Management System (OHSAS-18001:2007) 
  • ISO 14001: 2004 (Re-Certification) ‘Environment Management System’  

2011:

  • Best Green Belt Development. 

2012:

  • India Business Leader Award ‘First Generation Entrepreneur of the Year’
  • Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
  • ISO 14001: 2004 (Re-Certification) ‘Environment Management System’. 

2013:

  • ISO 14064 - 1: 2006 Green House Gas Accounting verification. 
  • May Day award for Best Management 

2014:

  • Winner of ‘Special Commendation’ for Golden Peacock Award for Corporate Social Responsibility 

2015:

  • Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
  • May Day award for Best Management 
  • ISO 14001: 2004 (Re-Certification) ‘Environment Management System’.  

2018:

  • Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
  • ISO 14001 : 2018 (Re- certification) ‘Environmental Management System’.
  • May Day award for Best Management 

Milestones

  • 1990: Inception of Divi’s as Divi’s Research Centre(DRC)
  • 1995: Setup First Manufacturing facility(Unit-1) near Hyderabad
  • 2000: First USFDA Inspection
  • 2002: Commenced New Manufacturing Facility (Unit 2) near Vishakhapatnam
  • 2003: Divi’s Labs listed on Indian Stock Exchange
  • 2007: Set up Nutraceuticals facility at Unit 2
  • 2008: First MFDS(Korea) inspection
  • 2010: Established  New Research Centre at Hyderabad
  • 2011: First EU GMP and Japan PMDA Inspection
  • 2012: First TGA Inspection
  • 2013: First Slovenian Medicines Agency inspection for Unit-II
  • 2014: Divi’s reaches a milestone of 8700 employees
  • 2014: First COFEPRIS inspection
  • 2015: New corporate office inaugurated at Hyderabad
  • 2015: New Pilot block with 160 Reactors and Kilo Lab
  • 2016: First Anvisa (Brazil) inspection
  • 2017: Divi’s reaches a milestone of 11,000 employees and becomes one of the largest employers in the combined state of Telangana/Andhra Pradesh
  • 2017: Reaches the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad
  • 2018: Market capital of $5B Reached
  • 2018: 10 new production blocks commissioned
  • 2018: Expanded the product portfolio to over 30 products
  • 2019: Setting up Manufacturing plant at Kakinada
  • 2019: Additional investment of $250M towards expansion of production blocks in Unit -I and Unit- II

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.96%
1 Week
+0.01%
1 Month
+11.19%
3 Month
+23.86%
6 Month
+43.74%
1 Year
+99.86%
2 Year
+192.99%
5 Year
+304.16%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 27.15 25.99 28.31 26.37 28.91 21.98 15.55 21.00 19.30
Return on Capital Employed (%) 34.20 33.21 36.04 33.06 35.57 28.75 21.68 28.50 25.36
Return on Assets (%) 21.20 19.17 19.92 18.21 22.49 17.21 11.12 15.78 15.11

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 2,132 2,501 2,963 3,495 4,293 5,357 5,925 6,957 7,310
Non Curr. Liab. 71 470 650 842 85 1,412 1,769 991 295
Curr. Liab. 554 554 627 776 520 659 653 847 1,821
Minority Int.
Equity & Liab. 2,757 3,525 4,241 5,112 4,898 7,429 8,347 8,795 9,425
Non Curr. Assets 1,006 1,661 1,984 2,340 1,871 3,418 3,812 4,145 3,851
Curr. Assets 1,751 1,864 2,256 2,772 3,027 4,011 4,535 4,650 5,574
Misc. Exp. not W/O
Total Assets 2,757 3,525 4,241 5,112 4,898 7,429 8,347 8,795 9,425

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 1,864 2,145 2,532 3,115 3,776 4,064 3,891 4,946 5,394
Other Income 56 45 71 45 97 75 113 156 190
Total Income 1,920 2,190 2,603 3,160 3,874 4,139 4,005 5,102 5,584
Total Expenditure -1,173 -1,329 -1,517 -1,949 -2,358 -2,617 -2,629 -3,073 -3,571
PBIDT 747 861 1,086 1,211 1,516 1,522 1,376 2,029 2,013
Interest -5 -3 -3 -3 -5 -3 -2 -5 -7
Depreciation -62 -77 -92 -136 -118 -123 -142 -169 -186
Taxation -147 -179 -218 -221 -267 -335 -354 -502 -443
Exceptional Items
PAT 533 602 773 852 1,126 1,060 877 1,353 1,377

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 338 480 557 826 1,038 1,150 776 954 1,216
Cash Fr. Inv. -204 -255 -305 -521 -406 -1,140 -478 -685 -83
Cash Fr. Finan. -131 -231 -249 -303 -631 2 -314 -246 -1,091
Net Change 3 -5 3 3 0 13 -17 23 41
Cash & Cash Eqvt 17 12 15 18 18 -4 -21 2 43

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 52.01 52.01 52.00 51.97 51.97 51.96 51.95 51.95 51.95
Public 47.99 47.99 48.00 48.03 48.03 48.04 48.05 48.05 48.05
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 22 Jul 2021
Copy of Newspaper Publication
Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Tue, 20 Jul 2021
Book Closure
Divi's Laboratories Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 20-Aug-2021 to 22-Aug-2021 for the purpose of Dividend.
Tue, 20 Jul 2021
Dividend Updates
Divi's Laboratories Limited has informed the Exchange about Dividend Updates

Technical Scans View Details

Thu, 29 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 703.00 +2.2%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,672.65 -1.2%
Cipla Ltd. 71,170.06 883.10 -0.8%
Cadila Healthcare Ltd. 58,547.84 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,028.55 0.0%
Aurobindo Pharma Ltd. 53,214.94 908.25 -0.8%
Piramal Enterprises Ltd. 52,639.21 2,310.60 +0.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 703.00 +2.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 29.59 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 908.25 -0.8%
Piramal Enterprises Ltd. Consolidated 2021-03 39.51 2,310.60 +0.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.00 +2.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 3.88 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 908.25 -0.8%
Piramal Enterprises Ltd. Consolidated 2021-03 1.54 2,310.60 +0.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.00 +2.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 0.18 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 908.25 -0.8%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,310.60 +0.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.00 +2.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 10.09 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 908.25 -0.8%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,310.60 +0.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.00 +2.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 12.53 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 908.25 -0.8%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,310.60 +0.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.00 +2.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 908.25 -0.8%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,310.60 +0.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.00 +2.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 908.25 -0.8%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,310.60 +0.0%